Published in J Med Genet on October 01, 1983
Two mutant alleles of the human cytochrome P-450db1 gene (P450C2D1) associated with genetically deficient metabolism of debrisoquine and other drugs. Proc Natl Acad Sci U S A (1988) 1.82
Genetic aspects of the polymodally distributed sulphoxidation of S-carboxymethyl-L-cysteine in man. Br J Clin Pharmacol (1984) 1.29
Cytochrome P450 2D6. Pharmacogenet Genomics (2009) 1.22
Drug metabolism and pharmacogenetics: the British contribution to fields of international significance. Br J Pharmacol (2006) 1.14
Polymorphic hydroxylation of perhexiline maleate in man. J Med Genet (1984) 1.11
Evidence for polymorphic oxidation of sparteine in Japanese subjects. Br J Clin Pharmacol (1987) 0.99
Testing for bimodality in frequency distributions of data suggesting polymorphisms of drug metabolism--hypothesis testing. Br J Clin Pharmacol (1989) 0.99
Debrisoquine oxidation phenotype and susceptibility to lung cancer. Br J Clin Pharmacol (1990) 0.97
A dose-effect study of the in vivo inhibitory effect of quinidine on sparteine oxidation in man. Br J Clin Pharmacol (1990) 0.91
No evidence for the presence of poor metabolizers of sparteine in an Amerindian group: the Cunas of Panama. Br J Clin Pharmacol (1986) 0.91
Correlations among the metabolic ratios of three test probes (metoprolol, debrisoquine and sparteine) for genetically determined oxidation polymorphism in a Japanese population. Br J Clin Pharmacol (1990) 0.83
Detection and characterization of human serum antibodies to polycyclic aromatic hydrocarbon diol-epoxide DNA adducts. J Clin Invest (1988) 0.83
Sparteine oxidation polymorphism: a family study. Br J Clin Pharmacol (1986) 0.82
Polymorphism of debrisoquine hydroxylation among Finns and Lapps. Br J Clin Pharmacol (1988) 0.82
Sparteine oxidation polymorphism in Greenlanders living in Denmark. Br J Clin Pharmacol (1986) 0.80
The gene CYP3 encoding P450pcn1 (nifedipine oxidase) is tightly linked to the gene COL1A2 encoding collagen type 1 alpha on 7q21-q22.1. Am J Hum Genet (1988) 0.79
Phenotypic debrisoquine 4-hydroxylase activity among extensive metabolizers is unrelated to genotype as determined by the Xba-I restriction fragment length polymorphism. Br J Clin Pharmacol (1991) 0.78
S-mephenytoin, sparteine and debrisoquine oxidation: genetic polymorphisms in a Turkish population. Br J Clin Pharmacol (1994) 0.78
Proceedings of the British Pharmacological Society. Amsterdam, 2nd-4th July 1986. Abstracts. Br J Pharmacol (1986) 0.75
A new, sensitive graphical method for detecting deviations from the normal distribution of drug responses: the NTV plot. Br J Clin Pharmacol (1991) 0.75
On mixtures of three normal populations caused by monogenic inheritance: application to desipramine metabolism. J Psychiatry Neurosci (1994) 0.75
Proceedings of the British Pharmacological Society, Clinical Pharmacology Section. 5-7 April 1989, Bristol. Abstracts. Br J Clin Pharmacol (1989) 0.75
Polymorphic hydroxylation of Debrisoquine in man. Lancet (1977) 9.36
A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population. J Med Genet (1980) 5.68
Defective N-oxidation of sparteine in man: a new pharmacogenetic defect. Eur J Clin Pharmacol (1979) 3.78
Polymorphic oxidation of sparteine and debrisoquine: related pharmacogenetic entities. Clin Pharmacol Ther (1982) 2.26
A simple method of resolution of a distribution into gaussian components. Biometrics (1967) 2.20
Testing of single locus hypotheses where there is incomplete separation of the phenotypes. Am J Hum Genet (1967) 1.74
Evidence for an enzymatic defect in the 4-hydroxylation of debrisoquine by human liver. Br J Clin Pharmacol (1981) 1.47
In vitro metabolism of sparteine by human liver: competitive inhibition by debrisoquine. Can J Physiol Pharmacol (1982) 1.13
Chicken liver ribosomes: characterization of cross-reaction and inhibition of some functions by antibodies prepared against Escherichia coli ribosomal proteins L7 and L12. J Mol Biol (1976) 12.86
Two shorter forms of the CES-D (Center for Epidemiological Studies Depression) depression symptoms index. J Aging Health (1993) 11.92
Polymorphic hydroxylation of Debrisoquine in man. Lancet (1977) 9.36
Changes in physicians' attitudes toward telling the cancer patient. JAMA (1979) 7.75
An improved and simplified method of detecting the acetylator phenotype. J Med Genet (1969) 6.40
Natural history of mild cognitive impairment in older persons. Neurology (2002) 6.09
Mild cognitive impairment is related to Alzheimer disease pathology and cerebral infarctions. Neurology (2005) 5.76
A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population. J Med Genet (1980) 5.68
Biliary excretion of foreign compounds. Biphenyl, stilboestrol and phenolphthalein in the rat: molecular weight, polarity and metabolism as factors in biliary excretion. Biochem J (1967) 5.33
Annual incidence of Alzheimer disease in the United States projected to the years 2000 through 2050. Alzheimer Dis Assoc Disord (2001) 5.09
Use of brief cognitive tests to identify individuals in the community with clinically diagnosed Alzheimer's disease. Int J Neurosci (1991) 4.53
More on SI units. N Engl J Med (1992) 4.34
Pain from distension of the pelvic colon by inflating a balloon in the irritable colon syndrome. Gut (1973) 4.28
Steady-state plasma levels of nortriptyline in twins: influence of genetic factors and drug therapy. Br Med J (1969) 4.21
Latent Semantic Indexing of medical diagnoses using UMLS semantic structures. Proc Annu Symp Comput Appl Med Care (1991) 4.09
Biliary excretion of foreign compounds. Benzene and its derivatives in the rat. Biochem J (1967) 3.97
Lowry determination of protein in the presence of Triton X-100. Anal Biochem (1975) 3.94
Polymorphism of carbon oxidation of drugs and clinical implications. Br Med J (1978) 3.90
Maintaining mobility in late life. I. Demographic characteristics and chronic conditions. Am J Epidemiol (1993) 3.74
Cerebral infarctions and the likelihood of dementia from Alzheimer disease pathology. Neurology (2004) 3.61
Nomenclature for N-acetyltransferases. Pharmacogenetics (1995) 3.59
Proneness to psychological distress is associated with risk of Alzheimer's disease. Neurology (2003) 3.59
Prevalence of parkinsonian signs and associated mortality in a community population of older people. N Engl J Med (1996) 3.48
Established populations for epidemiologic studies of the elderly: study design and methodology. Aging (Milano) (1993) 3.47
Depressive symptoms, cognitive decline, and risk of AD in older persons. Neurology (2002) 3.40
Fibrodysplasia ossificans progressiva. The clinical features and natural history of 34 patients. J Bone Joint Surg Br (1982) 3.39
Education modifies the relation of AD pathology to level of cognitive function in older persons. Neurology (2003) 3.35
Age-specific incidence of Alzheimer's disease in a community population. JAMA (1995) 3.09
Effect of organic contamination upon microbial distributions and heterotrophic uptake in a Cape Cod, Mass., aquifer. Appl Environ Microbiol (1984) 3.06
Denitrification in san francisco bay intertidal sediments. Appl Environ Microbiol (1984) 3.03
Delirium. The occurrence and persistence of symptoms among elderly hospitalized patients. Arch Intern Med (1992) 2.92
Cognitive activity and incident AD in a population-based sample of older persons. Neurology (2002) 2.77
Antipsychotic drug-induced movement disorders in schizophrenics in relation to CYP2D6 genotype. Br J Psychiatry (1997) 2.71
Depressive symptoms and cognitive decline in a community population of older persons. J Neurol Neurosurg Psychiatry (2004) 2.67
A prospective study of incident comprehensive medical home care use among the elderly. Am J Public Health (1988) 2.67
Social resources and cognitive decline in a population of older African Americans and whites. Neurology (2004) 2.66
Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor. Science (1993) 2.60
Relation of cerebral infarctions to dementia and cognitive function in older persons. Neurology (2003) 2.60
Phosphate-regulated inactivation of the kinase PHO80-PHO85 by the CDK inhibitor PHO81. Science (1994) 2.57
Biliary excretion in foreign compounds. Sulphonamide drugs in the rat. Biochem J (1967) 2.53
Biliary excretion in foreign compounds. Species difference in biliary excretion. Biochem J (1967) 2.52
Change in body mass index and risk of incident Alzheimer disease. Neurology (2005) 2.48
Cognitive decline in incident Alzheimer disease in a community population. Neurology (2010) 2.41
Impaired oxidation of debrisoquine in patients with perhexiline neuropathy. Br Med J (Clin Res Ed) (1982) 2.39
Apolipoprotein E epsilon4 allele, AD pathology, and the clinical expression of Alzheimer's disease. Neurology (2003) 2.32
Cognitive activity in older persons from a geographically defined population. J Gerontol B Psychol Sci Soc Sci (1999) 2.31
The metabolism of [14C]-debrisoquine in man. Br J Clin Pharmacol (1979) 2.29
Correlates of cognitive function in an elderly community population. Am J Epidemiol (1988) 2.26
Measured context-sensitive half-times of remifentanil and alfentanil. Anesthesiology (1995) 2.26
Chiral bis(oxazoline) copper(II) complexes: versatile catalysts for enantioselective cycloaddition, Aldol, Michael, and carbonyl ene reactions. Acc Chem Res (2000) 2.22
Age of Neoproterozoic bilatarian body and trace fossils, White Sea, Russia: implications for metazoan evolution. Science (2000) 2.21
Terminal decline in cognitive function. Neurology (2003) 2.18
Metabolic oxidation phenotypes as markers for susceptibility to lung cancer. Nature (1984) 2.17
ON A CASE OF SEPTICAEMIA TREATED BY INTRAVENOUS INJECTION OF EUSOL. Br Med J (1915) 2.16
Body malodour syndromes. Lancet (1995) 2.12
Nitrogen Fixation in Grasses Inoculated with Spirillum lipoferum. Science (1976) 2.09
Interindividual and interspecies variation in the metabolism of the hallucinogen 4-methoxyamphetamine. Xenobiotica (1979) 2.07
Science, medicine, and the future: Pharmacogenetics. BMJ (2000) 2.06
Cognitive activity and cognitive decline in a biracial community population. Neurology (2003) 2.06
False positives with current carbocisteine protocol for sulphoxidation phenotyping. Lancet (1990) 2.05
Testing for a change-point in registry data with an example on hypospadias. Stat Med (1988) 2.02
Statins, incident Alzheimer disease, change in cognitive function, and neuropathology. Neurology (2008) 1.97
Routine use of buccal oxytocin after amniotomy for induction of labour. Br Med J (1966) 1.96
Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels. Cancer Res (1997) 1.96
Trimethylaminuria: the fish malodor syndrome. Drug Metab Dispos (2001) 1.96
Epidemiology of disability in the oldest old: methodologic issues and preliminary findings. Milbank Mem Fund Q Health Soc (1985) 1.94
Cadaveric study of movement of an unstable atlanto-axial (C1/C2) cervical segment during laryngoscopy and intubation using the Airtraq(®) , Macintosh and McCoy laryngoscopes. Anaesthesia (2014) 1.93
Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations. Pharmacogenetics (1997) 1.92
Histological grade and other prognostic factors in relation to survival of patients with breast cancer. Br J Cancer (1979) 1.92
Trypanosoma brucei: Miniature anion-exchange centrifugation technique for detection of low parasitaemias: Adaptation for field use. Trans R Soc Trop Med Hyg (1979) 1.92
Acute delirium and functional decline in the hospitalized elderly patient. J Gerontol (1993) 1.91
Nomenclature for human CYP2D6 alleles. Pharmacogenetics (1996) 1.91
Reovirus infection and tissue injury in the mouse central nervous system are associated with apoptosis. J Virol (1997) 1.90
Dietary precursors of trimethylamine in man: a pilot study. Food Chem Toxicol (1999) 1.90
Temporal course of depressive symptoms during the development of Alzheimer disease. Neurology (2010) 1.87
Analysis of change in self-reported physical function among older persons in four population studies. Am J Epidemiol (1996) 1.86
Quantitation of glycosaminoglycan hexosamine using 3-methyl-2-benzothiazolone hydrazone hydrochloride. Anal Biochem (1979) 1.85
The actylation of sulamethazine and sulfamethoxypyridazine by human subjects. Clin Pharmacol Ther (1968) 1.85
Poor metabolisers of debrisoquine reveal their true colours. Lancet (1989) 1.84
Sputum examination for the diagnosis of Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. Am Rev Respir Dis (1986) 1.84
Missense mutation in flavin-containing mono-oxygenase 3 gene, FMO3, underlies fish-odour syndrome. Nat Genet (1997) 1.83
Cognitive decline after hospitalization in a community population of older persons. Neurology (2012) 1.83
Empirical, automated vocabulary discovery using large text corpora and advanced natural language processing tools. Proc AMIA Annu Fall Symp (1996) 1.81
The metabolic fate of amphetamine in man and other species. Biochem J (1970) 1.80
Social networks and disability transitions across eight intervals of yearly data in the New Haven EPESE. J Gerontol B Psychol Sci Soc Sci (1999) 1.79
A fibronectin receptor on Candida albicans mediates adherence of the fungus to extracellular matrix. J Infect Dis (1991) 1.78
Educational attainment and cognitive decline in old age. Neurology (2009) 1.78
The exogenous origin of trimethylamine in the mouse. Metabolism (1992) 1.78
The biliary excretion of tartrazine. Sex differences in the rat and species differences in the rat, guinea-pig and rabbit. J Pharm Pharmacol (1972) 1.77
The polymorphic acetylation of sulphapyridine in man. J Med Genet (1972) 1.72
A population-based longitudinal study of cognitive functioning in the menopausal transition. Neurology (2003) 1.71
Polymorphisms of oxidation at carbon centers of drugs and their clinical significance. Drug Metab Rev (1979) 1.71